Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 230-238

  Lee, W R ^a   Hanks, G E ^a   Hanlon, A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0031014008     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.230     Document Type: Article

References (25)

1. Lee WR, Hanks GE, Schultheiss TE, et al: Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 13:464-469, 1995
2. Partin AW, Pound CR, Clemens JQ, et al: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20:713-725, 1993
3. Zagars GK: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy (see comments). J Urol 152:1786-1791, 1994
4. Hanks GE, D'Amico A, Epstein BE, et al: Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time (see comments), Int J Radiat Oncol Biol Phys 27:125-127, 1993
5. Pollack A, Zagars GK, Kavadi VS: Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74:670-678, 1994
6. Soffen EM, Hanks GE, Hwang CC, et al: Conformal static field therapy for low volume low grade prostate cancer with rigid immobilization. Int J Radiat Oncol Biol Phys 20:141-146, 1991
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
9. Peto R, Pike MC, Armitage P: Design and analysis of randomized trials requiring prolonged observation of each patient II. Analysis and examples. Br J Cancer 35:1-39, 1977
10. Oesterling JE: Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991
11. Willett CG, Zietman AL, Shipley WU, et al: The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 151:1579-1581, 1994
12. Hanks GE, Perez CA, Kozar M, et al: PSA confirmation of cure at 10 years of the T1b, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 30:289-293, 1994
13. Lee WR, Hanlon A, Hanks GE: Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival. J Urol 156:450-453, 1996
14. Hanks GE, Hanlon AL, Lee WR, et al: Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34:549-553, 1996
15. Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol 141:1084-1087, 1989
16. Kaplan I, Prestridge BR, Cox RS, et al: Prostate specific antigen after irradiation for prostatic carcinoma. J Urol 144:1172-1176, 1990
17. D'Amico AD, Hanks GE: Linear regressive analysis using PSA doubling time predicts tumor biology and clinical outcome in prostate cancer. Cancer 72:2638-2643, 1993
18. Stamey TA, Ferrari MK, Schmid H-P: The value of serial prostate-specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of the patients. J Urol 150:1856-1859, 1993
19. Lee WR, Hanks GE, Corn BW, et al: Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys 31:21-24, 1995
20. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology 43:649-659, 1994
21. Hanks GE, Martz KL, Diamond JJ: The effect of dose on local control of prostate cancer. Int J Radist Oncol Biol Phys 15:1299-1305, 1988
22. Zietman AL, Dallow KC, McManus PL, et al: Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 47:236-239, 1996
23. Sanders H, Smith E, Woodward M, et al: The use of PSA to predict bone metastases in recurrence after definitive local therapy for prostate cancer. J Urol 153:238A, 1995 (abstr) (suppl 1)
24. Lee HJ, Dicker AP, Schwartz LH, et al: Evaluation of prostate-specific antigen velocity, bone scanning and CT in determining regional and distant failure after 3D conformal radiation therapy for prostate cancer. Radiology 197:330, 1995 (abstr) (suppl 1)
25. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen dependent tumors. Cancer 71:2782-2790, 1993